Savara Inc. (SVRA)
| Market Cap | 1.29B +156.6% |
| Revenue (ttm) | n/a |
| Net Income | -129.48M |
| EPS | -0.56 |
| Shares Out | 253.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,204,873 |
| Open | 5.27 |
| Previous Close | 5.30 |
| Day's Range | 5.04 - 5.30 |
| 52-Week Range | 1.98 - 7.01 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 10.81 (+112.38%) |
| Earnings Date | May 12, 2026 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SVRA stock is "Strong Buy." The 12-month stock price target is $10.81, which is an increase of 112.38% from the latest price.
News
Savara Transcript: AGM 2026
The meeting covered director elections, amendments to the certificate of incorporation and incentive plan, auditor ratification, and executive compensation. All proposals passed, and a Q&A session followed for stockholders.
Savara Transcript: Jefferies Global Healthcare Conference 2026
MOLBREEVI, an inhaled biologic for autoimmune PAP, is under FDA review with a PDUFA date in November and strong confidence in approval. The US market is estimated at 5,500 patients, with pricing set at $400,000–$500,000 per year and a robust launch plan in place. High retention and safety in trials support broad use, including in mild cases.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the manage...
Savara presents poster at ATS 2026 International Conference on IMPALA-2
Savara (SVRA) presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind…
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 Internati...
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 Internati...
Savara Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
MOLBREEVI, an inhaled GM-CSF therapy for aPAP, is nearing a key regulatory decision with strong clinical data and significant payer interest. The company is actively expanding diagnosis and awareness, preparing for a U.S. launch, and considering future global opportunities.
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 20...
Savara reports Q1 EPS (15c), consensus (14c)
“With approximately $203M in cash and, upon MOLBREEVI approval, access to up to an additional $150Min non-dilutive capital through debt and royalty structures, we remain well capitalized to fund globa...
Savara Reports First Quarter Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first qua...
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Savara Quarterly report: Q1 2026
Savara has published its Q1 2026 quarterly earnings report on May 12, 2026.
Savara Earnings release: Q1 2026
Savara released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the manage...
Savara Proxy statement: Proxy filing
Savara filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Savara Proxy statement: Proxy filing
Savara filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Savara assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for…
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new empl...
Savara says FDA extended review for Molgramostim BLA
Savara (SVRA) “announced that the FDA has extended the review period for the molgramostim BLA in autoimmune PAP by three months. The Agency is reviewing the molgramostim BLA under Priority…
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended th...
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two ...
Savara Proxy statement: Proxy filing
Savara filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Savara announces MHRA accepted submission of Molbreevi MAA
Savara (SVRA) announced that the MHRA has accepted the submission of the Molbreevi MAA for the treatment of autoimmune PAP in the U.K. The MAA was accepted under Accelerated Review…
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the MHRA has accepted t...
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.